Who are Rd's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Venetoclax; Rituximab, Venclexta, Ixempra Kit, Venetoclax (VEN), VEN, Perazyl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Rd — Competitive Intelligence Brief

Rd (Rd) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BCL-2 inhibitor. Area: Oncology.

marketed BCL-2 inhibitor BCL-2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Rd (Rd) — Ascentage Pharma Group Inc.. Rd is a BCL-2 family protein inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rd TARGET	Rd	Ascentage Pharma Group Inc.	marketed	BCL-2 inhibitor	BCL-2
Venetoclax; Rituximab	venetoclax-rituximab	Pfizer	marketed	BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)	BCL-2 (venetoclax); CD20 (rituximab)	N/A
Venclexta	venetoclax	AbbVie	marketed	BCL-2 Inhibitor [EPC]	Apoptosis regulator Bcl-2	2014-01-01
Ixempra Kit	IXABEPILONE	R-Pharm Us Llc	marketed	Microtubule Inhibitor	Apoptosis regulator Bcl-2	2007-01-01
Venetoclax (VEN)	Venetoclax (VEN)	Nanfang Hospital, Southern Medical University	marketed	BCL-2 inhibitor	BCL-2
VEN	VEN	Janssen Research & Development, LLC	marketed	BCL-2 inhibitor	BCL-2
Perazyl	CHLORCYCLIZINE		marketed	chlorcyclizine	Apoptosis regulator Bcl-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-05-26 — Venclexta · 9174982 · US
2031-06-27 — Venclexta · 8546399 · US
2031-11-21 — Venclexta · 10730873 · US
2032-01-29 — Venclexta · 8722657 · US
2032-05-23 — Venclexta · 11369599 · US
2033-09-06 — Venclexta · 11110087 · US
2033-09-06 — Venclexta · 11590128 · US
2033-09-06 — Venclexta · 10993942 · US
2033-09-06 — Venclexta · 9539251 · US
2033-09-06 — Venclexta · 11413282 · US

Sponsor landscape (BCL-2 inhibitor class)

Ascentage Pharma Group Inc. · 2 drugs in this class
Grupo Argentino de Tratamiento de la Leucemia Aguda · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
NHS Greater Glasgow and Clyde · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class
PrECOG, LLC. · 1 drug in this class
Stichting Hemato-Oncologie voor Volwassenen Nederland · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rd — Competitive Intelligence Brief. https://druglandscape.com/ci/rd. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab